|
BHLHB9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.09798844963416E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.81306139177696E-12 |
| Normal-vs-Stage2 |
8.1869000001511E-07 |
| Normal-vs-Stage3 |
5.75983705175531E-13 |
| Normal-vs-Stage4 |
1.62481139653892E-12 |
| Stage1-vs-Stage2 |
6.392500E-02 |
| Stage1-vs-Stage3 |
1.527400E-01 |
| Stage1-vs-Stage4 |
2.17909999999932E-05 |
| Stage2-vs-Stage3 |
1.071900E-02 |
| Stage2-vs-Stage4 |
3.97880000000406E-05 |
| Stage3-vs-Stage4 |
1.207570E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.14361861594625E-12 |
| Normal-vs-AfricanAmerican |
1.5655999999975E-05 |
| Normal-vs-Asian |
3.42015304966026E-12 |
| Caucasian-vs-AfricanAmerican |
2.438600E-01 |
| Caucasian-vs-Asian |
9.670400E-01 |
| AfricanAmerican-vs-Asian |
3.421400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.32385246998501E-12 |
| Normal-vs-Female |
4.07263112123246E-12 |
| Male-vs-Female |
7.926200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.14634993006757E-12 |
| Normal-vs-Age(41-60Yrs) |
9.35340693786202E-12 |
| Normal-vs-Age(61-80Yrs) |
6.10456130090142E-12 |
| Normal-vs-Age(81-100Yrs) |
1.991710E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.855800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.717600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.868000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.105000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.546000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.170400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.77019999999528E-05 |
| Classical-VS-Follicular |
1.250300E-02 |
| Classical-VS-Other |
8.472200E-01 |
| Classical-VS-Normal |
9.95148408122759E-12 |
| Tall-VS-Follicular |
8.14189999864823E-08 |
| Tall-VS-Other |
2.419400E-01 |
| Tall-VS-Normal |
1.62503344114384E-12 |
| Follicular-VS-Other |
5.925600E-01 |
| Follicular-VS-Normal |
1.13839999649201E-08 |
| Other-VS-Normal |
5.882600E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.91160462196194E-11 |
| Normal-vs-N1 |
1.62636570877339E-12 |
| N0-vs-N1 |
1.012500E-04 |
|
|
